<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02490046</url>
  </required_header>
  <id_info>
    <org_study_id>14/0384</org_study_id>
    <nct_id>NCT02490046</nct_id>
  </id_info>
  <brief_title>D-mannose for the Prevention of UTIs in Multiple Sclerosis</brief_title>
  <official_title>Single Centre Open-label Feasibility Study Evaluating the Use of D-mannose in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCLH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to explore the feasibility of using D-mannose, a commonly used food
      supplement, in persons with multiple sclerosis reporting recurrent urinary tract infections.
      Twenty persons with multiple sclerosis (10 patients using catheters and 10 not using
      catheters) reporting recurrent urinary tract infections will receive D-mannose 1.5 grams
      twice daily for 16 weeks duration.

      This will be explored through:

        1. Assessing compliance to a 16-week course of D-mannose

        2. Quantifying the number of prescriptions for antibiotics during the 16 weeks course of
           D-mannose
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Informed consent procedure: Potential participants will be approached in clinic and given a
      patient information sheet and adequate time will be given for the individual to read through
      the patient information sheet and for clarification of any queries or concerns. Informed
      consent will be obtained by one of the investigators involved in the conduct of the study
      prior to participation in the trial, following adequate explanation of the aims, methods,
      anticipated benefits and potential hazards of the study.

      Screening Period: Before any screening procedures occur, participants will sign an Informed
      Consent Form.

      During the screening evaluation the following procedures will be conducted and recorded for
      all patients:

        -  Informed Consent

        -  Evaluation of compliance with inclusion and exclusion criteria

        -  Demography and Past Medical History

        -  Vital signs including weight

        -  Physical examination including neurological examination

        -  Review of concomitant medications

      Baseline assessments: A urine sample will be tested for an infection using Urine multistix in
      the Department of Uro-neurology, which is a routine clinical practice. Participants will
      enter a discussion about the symptoms of a urinary tract infection and be taught the use of
      Urine multistix. They will complete standardised validated questionnaires for overactive
      bladder syndrome (ICIQ-OAB, sf-Qualiveen® and EQ5D-5L™).

      Treatment procedures: Patients will receive D-mannose powder to be used 1.5 gm (one
      level-teaspoon) twice daily, to be added to any beverage, for 16 weeks. D-mannose is classed
      as a food supplement and is widely available in the United Kingdom for purchase. D-Mannose
      will be sourced from D-Mannose Limited.

      Subsequent assessments: Compliance will be assessed by using a Usage diary, on which the use
      of D-mannose will be marked and any problems noted. Acceptability and tolerability to
      D-mannose will be assessed through the diary. Additionally, patients will be phoned after one
      week, and after 8 weeks, to enquire about well-being and compliance.

      Participants will be asked to note the number of prescriptions they receive during the 16
      week course in a urinary tract infection diary. Suspected self-reported urinary tract
      infections will be noted in a diary, as well as the results of the urine multistix. Standard
      clinical practice will be followed and participants with a suspected urinary tract infection
      will inform their general practitionner, mid-stream urine samples sent to the lab and
      antibiotic treatment started. Patients will continue to take D-mannose. The usage diary has
      to be sent by the patients every week.

      At week 16, patients will be asked to return for a second visit. Compliance and urinary tract
      infection diaries will be collected and reviewed. They will be asked to complete
      questionnaires (ICIQ-OAB, sf-Qualiveen® and EQ5D-5L™) and neurological status will be
      evaluated.

      The study will be conducted in accordance with the International Conference on Harmonization
      Good Clinical Practice guidelines and the Declaration of Helsinki, and within local laws and
      regulations.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compliance (self-usage diary and weight of returned containers of D-mannose)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Compliance to a 16-week course of D-mannose as assessed using a self-usage diary and weight of returned containers of D-mannose. The number of days the participant does not use D-mannose and reasons for non-use will be noted.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibiotic prescription (Number of prescriptions for antibiotics required)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Number of prescriptions for antibiotics required during the 16-week course</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Recurrent Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>MS and rec UTIs not using a catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>people with multiple sclerosis and recurrent urinary tract infections with spontaneous voiding Intervention- will be given D-mannose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MS and rec UTIs using a catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>people with multiple sclerosis and recurrent urinary tract infections using either urethral or suprapubic indwelling catheter or intermittent catheterisation Intervention- will be given D-mannose</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>D Mannose</intervention_name>
    <description>Patients in both arms will receive D-mannose powder to be used 1.5 gm (one level-teaspoon) twice daily, to be added to any beverage, for 16 weeks.</description>
    <arm_group_label>MS and rec UTIs not using a catheter</arm_group_label>
    <arm_group_label>MS and rec UTIs using a catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with a known diagnosis of Multiple sclerosis (all stages) who have been
             clinically stable for at least three months and reporting lower urinary tract
             symptoms.

          2. Patient with recurrent urinary tract infections, defined as having at least two
             urinary tract infections in the preceding six months or three or more urinary tract
             infections in the preceding one year. Urinary tract infections were defined
             retrospectively by patient self-report and confirmation by urine culture.

          3. Age over 18 years and below 65

          4. Females of childbearing potential using effective contraception if sexually active -
             oral contraceptive pill (&gt; 3 months use), condoms, intrauterine contraceptive device,
             depot injection

        Exclusion Criteria:

          1. Pregnancy or planning pregnancy

          2. Breastfeeding

          3. History of congenital urinary tract anomalies or interstitial cystitis

          4. History of diabetes mellitus

          5. Receiving antibiotic prophylaxis or cranberry extract preparations

          6. Current urinary tract infection

          7. Current vaginal infection

          8. Any known allergies to D-mannose
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jalesh Panicker, MD,FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLH NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jalesh Panicker, MD, FRCP</last_name>
    <phone>0203 448 4713</phone>
    <email>j.panicker@ucl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Véronique Phé, MD</last_name>
    <phone>0203 448 4713</phone>
    <email>Veronique.Phe@uclh.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The National Hospital for Neurology and Neurosurgery</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jalesh Panicker, MD, FRCP</last_name>
      <phone>020 344 84713</phone>
      <email>j.panicker@ucl.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Véronique Phé, MD</last_name>
      <phone>020 344 84713</phone>
      <email>Veronique.Phe@uclh.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Mahreen Pakzad, FRCS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jalesh Panicker, MD, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique Phé, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Nakipoglu GF, Kaya AZ, Orhan G, Tezen O, Tunc H, Ozgirgin N, Ak F. Urinary dysfunction in multiple sclerosis. J Clin Neurosci. 2009 Oct;16(10):1321-4. doi: 10.1016/j.jocn.2008.12.012. Epub 2009 Jun 27.</citation>
    <PMID>19560927</PMID>
  </reference>
  <reference>
    <citation>de Sèze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B; GENULF. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler. 2007 Aug;13(7):915-28. Epub 2007 Mar 15. Review.</citation>
    <PMID>17881401</PMID>
  </reference>
  <reference>
    <citation>The prevention and management of urinary tract infections among people with spinal cord injuries. National Institute on Disability and Rehabilitation Research Consensus Statement. January 27-29, 1992. J Am Paraplegia Soc. 1992 Jul;15(3):194-204. Review.</citation>
    <PMID>1500945</PMID>
  </reference>
  <reference>
    <citation>Hoffman JM, Wadhwani R, Kelly E, Dixit B, Cardenas DD. Nitrite and leukocyte dipstick testing for urinary tract infection in individuals with spinal cord injury. J Spinal Cord Med. 2004;27(2):128-32.</citation>
    <PMID>15162883</PMID>
  </reference>
  <reference>
    <citation>Stöhrer M, Blok B, Castro-Diaz D, Chartier-Kastler E, Del Popolo G, Kramer G, Pannek J, Radziszewski P, Wyndaele JJ. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol. 2009 Jul;56(1):81-8. doi: 10.1016/j.eururo.2009.04.028. Epub 2009 Apr 21.</citation>
    <PMID>19403235</PMID>
  </reference>
  <reference>
    <citation>Fowler CJ, Panicker JN, Drake M, Harris C, Harrison SC, Kirby M, Lucas M, Macleod N, Mangnall J, North A, Porter B, Reid S, Russell N, Watkiss K, Wells M. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2009 May;80(5):470-7. doi: 10.1136/jnnp.2008.159178. Review.</citation>
    <PMID>19372287</PMID>
  </reference>
  <reference>
    <citation>Leary SM, Porter B, Thompson AJ. Multiple sclerosis: diagnosis and the management of acute relapses. Postgrad Med J. 2005 May;81(955):302-8. Review.</citation>
    <PMID>15879043</PMID>
  </reference>
  <reference>
    <citation>Hennessey A, Robertson NP, Swingler R, Compston DA. Urinary, faecal and sexual dysfunction in patients with multiple sclerosis. J Neurol. 1999 Nov;246(11):1027-32.</citation>
    <PMID>10631634</PMID>
  </reference>
  <reference>
    <citation>Correale J, Fiol M, Gilmore W. The risk of relapses in multiple sclerosis during systemic infections. Neurology. 2006 Aug 22;67(4):652-9. Epub 2006 Jul 26.</citation>
    <PMID>16870812</PMID>
  </reference>
  <reference>
    <citation>Buljevac D, Flach HZ, Hop WC, Hijdra D, Laman JD, Savelkoul HF, van Der Meché FG, van Doorn PA, Hintzen RQ. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain. 2002 May;125(Pt 5):952-60.</citation>
    <PMID>11960885</PMID>
  </reference>
  <reference>
    <citation>Rakusa M, Murphy O, McIntyre L, Porter B, Panicker J, Fowler C, Scott G, Chataway J. Testing for urinary tract colonization before high-dose corticosteroid treatment in acute multiple sclerosis relapses: prospective algorithm validation. Eur J Neurol. 2013 Mar;20(3):448-52. doi: 10.1111/j.1468-1331.2012.03806.x. Epub 2012 Jul 21.</citation>
    <PMID>22816507</PMID>
  </reference>
  <reference>
    <citation>Everaert K, Lumen N, Kerckhaert W, Willaert P, van Driel M. Urinary tract infections in spinal cord injury: prevention and treatment guidelines. Acta Clin Belg. 2009 Jul-Aug;64(4):335-40. Review.</citation>
    <PMID>19810421</PMID>
  </reference>
  <reference>
    <citation>Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2012 Oct 17;10:CD001321. doi: 10.1002/14651858.CD001321.pub5. Review.</citation>
    <PMID>23076891</PMID>
  </reference>
  <reference>
    <citation>Gallien P, Amarenco G, Benoit N, Bonniaud V, Donzé C, Kerdraon J, de Seze M, Denys P, Renault A, Naudet F, Reymann JM. Cranberry versus placebo in the prevention of urinary infections in multiple sclerosis: a multicenter, randomized, placebo-controlled, double-blind trial. Mult Scler. 2014 Aug;20(9):1252-9. doi: 10.1177/1352458513517592. Epub 2014 Jan 8.</citation>
    <PMID>24402038</PMID>
  </reference>
  <reference>
    <citation>Michaels EK, Chmiel JS, Plotkin BJ, Schaeffer AJ. Effect of D-mannose and D-glucose on Escherichia coli bacteriuria in rats. Urol Res. 1983;11(2):97-102.</citation>
    <PMID>6346629</PMID>
  </reference>
  <reference>
    <citation>Kranjčec B, Papeš D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014 Feb;32(1):79-84. doi: 10.1007/s00345-013-1091-6. Epub 2013 Apr 30.</citation>
    <PMID>23633128</PMID>
  </reference>
  <results_reference>
    <citation>Compston A, Coles A. Multiple sclerosis. Lancet. 2002 Apr 6;359(9313):1221-31. Review. Erratum in: Lancet 2002 Aug 24;360(9333):648.</citation>
    <PMID>11955556</PMID>
  </results_reference>
  <results_reference>
    <citation>Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Disparities in the management of multiple sclerosis-related bladder symptoms. Neurology. 2007 Jun 5;68(23):1971-8.</citation>
    <PMID>17548546</PMID>
  </results_reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2015</study_first_submitted>
  <study_first_submitted_qc>July 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2015</study_first_posted>
  <last_update_submitted>July 1, 2015</last_update_submitted>
  <last_update_submitted_qc>July 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>D mannose</keyword>
  <keyword>multiple sclerosis</keyword>
  <keyword>recurrent urinary infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

